|Day's Range||42.38 - 42.72|
|52 Week Range||37.20 - 45.58|
|PE Ratio (TTM)||48.52|
|Dividend & Yield||1.95 (4.55%)|
|1y Target Est||N/A|
Gardasil is Merck's (MRK) leading vaccine franchise. Total sales for Gardasil in 1Q17 were $532.0 million, a ~41.0% rise over $378.0 million in 1Q16.
Merck stock has risen nearly 16.0% over the last 12 months. Analysts estimate that the stock has a potential to return 10.0% over the next 12 months.
Celldex Therapeutics and Agenus have promising oncology pipelines, but which is the better stock right now?